By Healthcare Edge Editorial Staff Octave Bioscience, Inc. said Founder William Hagstrom will become Chairman of the Board, while Doug Biehn is the new President and CEO. Mr. Biehn has over 20 years of experience in healthcare, building and scaling...

    By Healthcare Edge Editorial Staff SAB Biotherapeutics, Inc. (Nasdaq: SABS), which is trying to slow down the progression of type 1 diabetes, said it started trials of SAB-142 on humans in Australia. SAB-142 is the first fully-human anti-thymocyte...

Healthcare Edge and Exec Edge are please to provide complete video coverage of the third annual Palm Beach CorpGov Forum, which was held on Nov. 8, featuring a full day of panels and fireside chats. The event was composed of over...

By Karen E. Roman Alladapt Immunotherapeutics, Inc., a biopharmaceutical company developing treatment for Immunoglobulin E-mediated food allergy, said it received fast track designation by the U.S. Food and Drug Administration for ADP101, its multi-food oral immunotherapy. ADP101 is designed to...

    By Healthcare Edge Editorial Staff Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it has received a $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The...

  By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage company developing a fully-human treatment to delay the progress of type 1 diabetes, said its net loss narrowed in the third quarter. The net loss was $5.1 million,...

  By Karen E. Roman Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a company which develops biologic medicines, announced it has appointed Dorothy Clarke to its board of directors. Ms. Clarke previously held leadership roles at Johnson & Johnson for...

By Karen E. Roman Alladapt Immunotherapeutics, Inc., a clinical-stage company which develops therapeutics to address food allergies, announced data from its Phase 1/2 Harmony study which proves that ADP101, a multi-allergen oral immunotherapy (OIT), produced dose-dependent, clinically meaningful responses. The...

  By Karen E. Roman Promontory Therapeutics Inc., a clinical stage development company centered on small molecule immunotherapy in cancer, presented its latest results on its lead therapeutic candidate, PT-112. The results were exposed at the Society for Immunotherapy of...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) said it appointed Dr. James Bristol, an experienced biopharmaceutical executive with a background in research and drug discovery, to its Board of Directors. Before his retirement from Pfizer in 2007, Dr. Bristol...